The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
Open accessAbstract
Genetic loss of collagen VII causes recessive dystrophic epidermolysis bullosa (RDEB)-a severe skin fragility disorder associated with lifelong blistering and disabling progressive soft tissue fibrosis. Causative therapies for this complex disorder face major hurdles, and clinical implementation remains elusive. Here, we report an alternative evidence-based approach to ameliorate fibrosis and relieve symptoms in RDEB. Based on the findings that TGF-β activity is elevated in injured RDEB skin, we targeted TGF-β activity with losartan in a preclinical setting. Long-term treatment of RDEB mice efficiently reduced TGF-β signaling in chronically injured forepaws and halted fibrosis and subsequent fusion of the digits. In addition, proteomics analysis of losartan- vs. vehicle-treated RDEB skin uncovered changes in multiple proteins related to tissue inflammation. In line with this, losartan reduced inflammation and diminished TNF-α and IL-6 expression in injured forepaws. Collectively, the data argue that RDEB fibrosis is a consequence of a cascade encompassing tissue damage, TGF-β-mediated inflammation, and matrix remodeling. Inhibition of TGF-β activity limits these unwanted outcomes and thereby substantially ameliorates long-term symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa
Wagner, J. E., Ishida-Yamamoto, A., McGrath, J. A., Hordinsky, M., Keene, D. R., Woodley, D. T., Chen, M., Riddle, M. J., Osborn, M. J., Lund, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910501 · Cited by 374
Hinz, B. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0017-1 · Cited by 373
Cited by
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Has, C., Bauer, J. W., Bodemer, C., Bolling, M. C., Bruckner‐Tuderman, L., Diem, A., Fine, J. ‐., Heagerty, A., Hovnanian, A., Marinkovich, M. P., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18921 · Cited by 797
Self-citationBardhan, A., Bruckner-Tuderman, L., Chapple, I. L. C., Fine, J.-D., Harper, N., Has, C., Magin, T. M., Marinkovich, M. P., Marshall, J. F., McGrath, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0210-0 · Cited by 455
Self-citationMatrix molecules and skin biology
Nyström, A., & Bruckner-Tuderman, L. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2018.07.025 · Cited by 144
Self-citationNext generation human skin constructs as advanced tools for drug development
Abaci, H., Guo, Z., Doucet, Y., Jacków, J., & Christiano, A. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217712690 · Cited by 104
Metadata
- Authors
- Nyström, A., Thriene, K., Mittapalli, V., Kern, J. S., Kiritsi, D., Dengjel, J., & Bruckner‐Tuderman, L.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-07-20
- Volume
- 7
- Issue
- 9
- Pages
- 1211-1228
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W1870255478
- Cited by
- 180
- References
- 4
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. https://app.cochat.ai/papers/10.15252/emmm.201505061
- The paper
- Nyström, A., Thriene, K., Mittapalli, V., Kern, J. S., Kiritsi, D., Dengjel, J., & Bruckner‐Tuderman, L. (2015). Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201505061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.